Related Experiment Video
Updated: Feb 18, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
1.8K
Non-PCI/CABG therapies for refractory angina
1Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL; Department of Cardiology, Malcom Randall VA Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL.
Trends in Cardiovascular Medicine
|November 22, 2017
Summary
Refractory angina persists despite treatment. Management includes aggressive risk factor modification, optimized medical therapy with multiple agents, and novel treatments like ranolazine or enhanced external counterpulsation.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Refractory angina affects many patients despite current therapies.
- Persistent angina symptoms significantly impact quality of life.
Purpose of the Study:
- To outline comprehensive management strategies for refractory angina.
- To highlight the importance of aggressive risk factor modification and optimized medical therapy.
Main Methods:
- Review of current medical literature and treatment guidelines.
- Discussion of pharmacologic and non-pharmacologic therapeutic options.
Main Results:
- Optimized medical management is crucial, often requiring multiple medications.
- Novel agents like ranolazine and ivabradine show potential.
- Non-pharmacologic therapies including enhanced external counterpulsation and cardiac rehabilitation offer relief.
Conclusions:
- Aggressive risk factor modification and optimized medical management are essential for refractory angina.
- A multimodal approach combining pharmacologic and non-pharmacologic strategies is recommended for symptom control.
Related Concept Videos
01:26Angina IV: Management
328
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
328
01:27Coronary Artery Disease V: Interprofessional Care
314
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
314
01:27Peripheral Artery Disease III: Interprofessional Care
380
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
380
01:27Angina II: Classification
436
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
436
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
01:28Acute Coronary Syndrome IV: Interprofessional Care
313
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
313